Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 32.13 (+0.47), DXCM: 50.93 (+6.30), ANGO: 16.95 (+0.10), HOLX: 26.21 (-0.37)
Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 32.13 (+0.47), CYNO: 24.60 (-0.63), THOR: 26.93 (+0.83), ANGO: 16.95 (+0.10)
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 32.13 (+0.47), DXCM: 50.93 (+6.30), FMI: 24.75 (-0.03), ANGO: 16.95 (+0.10)
Teleflex Beats on Q3 Earnings & Revenues, Outlook Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:20PM CST
Teleflex Inc (TFX) reported adjusted earnings of $1.57 per share which outshined both the Zacks Consensus Estimate of $1.37 and year-ago earnings of $1.33.
CYNO: 24.60 (-0.63), FLDM: 28.90 (-0.24), TFX: 113.90 (-0.33), ANGO: 16.95 (+0.10)
Symmetry Medical Q3 Earnings & Revenues Miss, Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:10PM CST
Symmetry Medical Inc. (SMA) reported adjusted earnings per share of 11 cents in the third quarter of fiscal 2014, which missed the Zacks Consensus Estimates of 14 cents.
SMA: 9.27 (-0.21), CYNO: 24.60 (-0.63), FLDM: 28.90 (-0.24), ANGO: 16.95 (+0.10)
CryoLife Q3 Earnings Fall, Revenues Rise Y/Y; Shares Tank - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:00PM CST
CryoLife Inc. (CRY) reported adjusted earnings per share of 8 cents in the third quarter of fiscal 2014, lower than the year-ago earnings of 11 cents.
CYNO: 24.60 (-0.63), FLDM: 28.90 (-0.24), CRY: 10.06 (-0.23), ANGO: 16.95 (+0.10)
Mindray Medical Q3 Earnings in Line, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:07PM CST
Mindray Medical International Limited (MR) slashed its 2014 financial guidance in the face of increasing uncertainties in currency and other macro developments that could impact its performance in certain key markets.
ABMD: 32.13 (+0.47), FLDM: 28.90 (-0.24), ANGO: 16.95 (+0.10), MR: 29.99 (+0.34)
Techne Corp. (TECH) Q1 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:50PM CST
Techne Corp. (TECH) reported adjusted earnings of 85 cents per share in the first quarter fiscal 2015, which was lower than the Zacks Consensus Estimate of 87 cents.
CYNO: 24.60 (-0.63), FLDM: 28.90 (-0.24), TECH: 90.71 (-0.46), ANGO: 16.95 (+0.10)
Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:10PM CST
Abiomed Inc. (ABMD) reported second-quarter fiscal 2015 earnings of 9 cents per share, outshining the Zacks Consensus Estimate of 2 cents.
ABMD: 32.13 (+0.47), FLDM: 28.90 (-0.24), BEAT: 8.15 (-0.05), ANGO: 16.95 (+0.10)
Becton, Dickinson (BDX) Beats Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:03AM CST
Becton, Dickinson and Company (BDX) reported fourth-quarter fiscal 2014 earnings of $1.68 per share, which beat the Zacks Consensus Estimate by 3 cents.
BDX: 125.54 (-2.39), FLDM: 28.90 (-0.24), BEAT: 8.15 (-0.05), ANGO: 16.95 (+0.10)
Accuray (ARAY) Q1 Loss Wider Than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 12:30PM CST
Accuray Inc (ARAY) reported a loss of 28 cents per share in the first quarter of fiscal 2015, wider than the Zacks Consensus Estimate of a loss of 13 cents and a year-ago loss of 21 cents.
ATEC: 1.39 (-0.06), CYNO: 24.60 (-0.63), ARAY: 6.85 (-0.05), ANGO: 16.95 (+0.10)
Greatbatch Beats Q3 Earnings Estimates; Upgrades '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Based on its third-quarter results, the addition of CCC Medical Devices, and the forecast for the fourth quarter, Greatbatch raised its full-year 2014 revenue and adjusted earnings per share guidance.
ATEC: 1.39 (-0.06), CYNO: 24.60 (-0.63), GB: 48.90 (-0.05), ANGO: 16.95 (+0.10)
Luminex (LMNX) Upgraded to Strong Buy on Impressive Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 5:25PM CDT
Luminex Corporation (LMNX) posted encouraging third-quarter 2014 numbers on Oct 27, with adjusted earnings surpassing the Zacks Consensus Estimate by a wide margin of 120%.
ATEC: 1.39 (-0.06), CYNO: 24.60 (-0.63), LMNX: 18.04 (-0.75), ANGO: 16.95 (+0.10)
Uptrend Call Working As Angiodynamics Stock Rises 10.9% (ANGO)
Comtex SmarTrend(R) - Wed Oct 29, 9:25AM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 2 weeks, Angiodynamics has returned 10.86% as of today's recent price of $16.89.
ANGO: 16.95 (+0.10)
IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.39 (-0.06), EW: 122.76 (-0.81), IDXX: 145.16 (-0.75), ANGO: 16.95 (+0.10)
NanoKnife System Receives OPS Procedure Classification Codes in Germany
GlobeNewswire - Tue Oct 28, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the Germany Ministry of Health has issued an OPS (a procedure classification code) for the company's NanoKnife System. This process is the first step in securing reimbursement for new medical technologies in Germany.
ANGO: 16.95 (+0.10)
Edwards Lifesciences (EW) Worth Watching: Stock Up 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:25AM CDT
Edwards Lifesciences (EW) was a big mover last session, with shares rising 11% on the day.
BABY: 33.15 (-0.73), PACB: 6.52 (-0.01), EW: 122.76 (-0.81), ANGO: 16.95 (+0.10)
Quality Systems Misses on Q2 Fiscal Earnings by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:30PM CDT
Quality Systems' (QSII) revenues at the end of the quarter stood at $120.5 million, representing an increase of 8.5% from the year-ago revenues.
PACB: 6.52 (-0.01), QSII: 14.56 (-0.34), ANGO: 16.95 (+0.10), OMCL: 31.89 (-0.28)
Edwards Lifesciences Tops Q3 Earnings, Revenues; Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 11:10AM CDT
Edwards' (EW) successful new product launches and pipeline updates strongly position the company to drive solid organic sales growth in the coming quarters.
ATEC: 1.39 (-0.06), PACB: 6.52 (-0.01), EW: 122.76 (-0.81), ANGO: 16.95 (+0.10)
RTI Surgical (RTIX) Jumps: Stock Moves 12.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 8:46AM CDT
RTI Surgical (RTIX) was a big mover last session, with shares rising nearly 13% on the day.
ATEC: 1.39 (-0.06), RTIX: 5.09 (+0.02), EW: 122.76 (-0.81), ANGO: 16.95 (+0.10)